Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

Carla Casulo, MD, Jia Ruan, MD PhD, Nam H. Dang, MD PhD, Lia Gore, MD, Catherine Diefenbach, MD, Anne W Beaven, MD, Januario E. Castro, MD, Pierluigi Porcu, MD, Leonardo Faoro, MD, Jakob Dupont, MD, Ann Kapoun, PhD, Min Wang, PhD, Kristin McGuire, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 5108.

https://doi.org/10.1182/blood.V128.22.5108.5108

Published: 2016

Journal Articles

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Andre Goy, MD, Radhakrishnan Ramchandren, MD, Nilanjan Ghosh, MD PhD, Javier Munoz, MD, David S. Morgan, MD, Nam H. Dang, MD PhD, Mark Knapp, MD, Maria Delioukina, MD, Edwin C. Kingsley, MD, Anh Tran, BS, Jerry Ping, PhD, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, Jia Ruan, MD PhD

Blood (2016) 128 (22): 473.

https://doi.org/10.1182/blood.V128.22.473.473

Published: 2016

Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD

Blood (2014) 124 (21): 3097.

https://doi.org/10.1182/blood.V124.21.3097.3097

Published: 2014

Journal Articles

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Enrique Romaguera, Felipe Samaniego, MD, Jeffrey A. Silverman, Ph.D., Andreas H. Sarris, MD, PhD, Fernando Cabanillas, MD

Blood (2013) 122 (21): 3033.

https://doi.org/10.1182/blood.V122.21.3033.3033

Published: 2013

Journal Articles

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Randeep Sangha, Andrew Davies, PhD, Nam H. Dang, MD, PhD, Michinori Ogura, MD, PhD, David A. MacDonald, MD, Angela Volkert, Revathi Ananthakrishnan, Kenneth Luu, Joseph P. Boni, PhD, Erik Vandendries, MD, Yeow-Tee YT Goh, MD

Blood (2013) 122 (21): 1821.

https://doi.org/10.1182/blood.V122.21.1821.1821

Published: 2013

Journal Articles

Anti-Tumor Activity of Low Dose Ocaratuzumab in Previously Treated Follicular Lymphoma Patients with Low-Affinity CD16 Polymorphisms

Phuong H Le, MS, Andres Forero-Torres, MD, Nam H. Dang, MD, PhD, Mitchell R Smith, MD, PhD, Brian K Link, MD, Kristen N. Ganjoo, MD, Kensei Tobinai, MD, PhD, Minna Du, Adrienne O'Reilly, MS, Vinay Jain, MBBS, MD, FACP

Blood (2012) 120 (21): 4884.

https://doi.org/10.1182/blood.V120.21.4884.4884

Published: 2012

Journal Articles

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Raoul Herbrecht, David MacDonald, MD, FRCPC, Florian Weissinger, MD, Martin Wilhelm, MD, Charles Holladay, MS, MD, Nam H. Dang, MD, PhD, Peter Holman, MD, Paul Cernohous, MS, Jack Singer, MD, Richard H. van der Jagt, MD, FRCPC

Blood (2011) 118 (21): 1605.

https://doi.org/10.1182/blood.V118.21.1605.1605

Published: 2011

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Nam H. Dang, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, MD, Gregor Verhoef, MD, Peter Johnson, MD, Ama Z S Rohatiner, MD, Jonathan L. Kaufman, MD, Eva Gine, M.D., Bertrand Coiffier, MD, Myron S Czuczman, MD, James Foran, MD, Simon Durrant, MD, Steven Hua, PhD, Erik R. Vandendries, MD, PhD, Luis Fayad, MD

Blood (2009) 114 (22): 584.

https://doi.org/10.1182/blood.V114.22.584.584

Published: 2009

Journal Articles

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

Luis Fayad, Hemant Patel, PhD, Gregor Verhoef, Mitchell R. Smith, Peter W.M. Johnson, MD, FRCP, Myron S. Czuczman, MD, Bertrand Coiffier, Georg Hess, Eva Gine, Anjali Advani, MD, Fritz Offner, MD, Erik R. Vandendries, MD, PhD, Mark Shapiro, MD, PhD, FACP, Nam H. Dang, MD, PhD

Blood (2008) 112 (11): 266.

https://doi.org/10.1182/blood.V112.11.266.266

Published: 2008

Journal Articles

CD26 Expression on T-Cell Lines Is Associated with SDF-1α-Mediated Invasion and Phosphorylation of Signaling Molecules.

Pamela A. Havre, PhD, Masako Abe, PhD, Yasuyo Urasaki, PhD, Chikao Morimoto, MD, PhD, Nam H. Dang, MD, PhD

Blood (2007) 110 (11): 3572.

https://doi.org/10.1182/blood.V110.11.3572.3572

Published: 2007

Journal Articles

Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma.

Barbara Pro, MD, Luis Fayad, MD, Jorge Romaguera, MD, Michelle Fanale, MD, Anas Younes, MD, Fredrick B. Hagemeister, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, M.A. Rodriguez, MD, Larry Kwak, MD, PhD, Nam H. Dang, MD

Blood (2007) 110 (11): 3456.

https://doi.org/10.1182/blood.V110.11.3456.3456

Published: 2007

Journal Articles

Activity of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) in 22 Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Anas Younes, MD, Barbara Pro, MD, Maria A. Rodriguez, MD, Jorge E. Romaguera, MD, Peter McLaughlin, MD, Michael Wang, MD, Fredrick B. Hagemeister, MD, Nam H. Dang, MD, Sattva Neelapu, MD, Donald Podoloff, MD

Blood (2005) 106 (11): 2452.

https://doi.org/10.1182/blood.V106.11.2452.2452

Published: 2005

Journal Articles

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Peter McLaughlin, MD, Luis Fayad, MD, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Anas Younes, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Pamela L. Walker, RN, Maria A. Rodriguez, MD, Larry Kwak, MD, PhD, Barbara Pro, MD

Blood (2005) 106 (11): 3349.

https://doi.org/10.1182/blood.V106.11.3349.3349

Published: 2005

Journal Articles

Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Maria Rodriguez, MD, Andre Goy, MD, Jorge Romaguera, MD, Pamela L. Walker, RN, Anas Younes, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Luis Fayad, MD

Blood (2005) 106 (11): 3350.

https://doi.org/10.1182/blood.V106.11.3350.3350

Published: 2005

Journal Articles

Phase II Study of Sphingosomal Vincristine in CHOP+/ − Rituximab for Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients.

Maria Alma Rodriguez, MD, Nam H. Dang, MD, PhD, Luis Fayad, MD, Andre Goy, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Romaguera, MD, Anas Younes, MD, Fernando Cabanillas, MD

Blood (2005) 106 (11): 943.

https://doi.org/10.1182/blood.V106.11.943.943

Published: 2005

Journal Articles

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick B. Hagemeister, MD, Dan Jones, MD, PhD, Barry Samuels, MD, Maria A. Rodriguez, MD, Andre Goy, MD, Jorge E. Romaguera, MD, Pamela L. Walker, RN, Larry Kwak, MD, PhD, Luis Fayad, MD

Blood (2004) 104 (11): 2641.

https://doi.org/10.1182/blood.V104.11.2641.2641

Published: 2004

Journal Articles

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

Jorge Enrique Romaguera, MD, Luis Fayad, MD, Maria A. Rodriguez, MD, Fredrick B. Hagemeister, MD, Barbara Pro, MD, Peter McLaughlin, MD, Anas Younes, MD, Felipe Samaniego, MD, Andre Goy, MD, Andreas H. Sarris, MD, Ph.D., Nam H. Dang, MD, Ph.D., L. Jeffrey Medeiros, MD, Ruth Katz, MD, Harish Gagneja, MD, Barry I. Samuels, MD, Fernando Cabanillas, MD

Blood (2004) 104 (11): 128.

https://doi.org/10.1182/blood.V104.11.128.128

Published: 2004

Journal Articles

CD26/Dipeptidyl Peptidase IV (DPPIV) Regulates p38 Phosphorylation and Topoisomerase II Alpha Expression in the B-Lymphoma Line Jiyoye, Associated with Enhanced In Vitro and In Vivo Sensitivity to Doxorubicin.

Toshiko Yamochi, MD, PhD, Tadanori Yamochi, PhD, Ugur Aytac, PhD, Tsutomu Sato, MD, PhD, Chikao Morimoto, MD, Nam H. Dang, MD, PhD

Blood (2004) 104 (11): 3407.

https://doi.org/10.1182/blood.V104.11.3407.3407

Published: 2004

NARROW

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Anti-Tumor Activity of Low Dose Ocaratuzumab in Previously Treated Follicular Lymphoma Patients with Low-Affinity CD16 Polymorphisms

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

CD26 Expression on T-Cell Lines Is Associated with SDF-1α-Mediated Invasion and Phosphorylation of Signaling Molecules.

Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma.

Activity of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) in 22 Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Phase II Study of Sphingosomal Vincristine in CHOP+/ − Rituximab for Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients.

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

CD26/Dipeptidyl Peptidase IV (DPPIV) Regulates p38 Phosphorylation and Topoisomerase II Alpha Expression in the B-Lymphoma Line Jiyoye, Associated with Enhanced In Vitro and In Vivo Sensitivity to Doxorubicin.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only